PDS Biotechnology Corp — Director's Dealing 2015

Oct 8, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-10-06

Reporting Person: Leuthner Brian A (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-06	Common Stock	C	2672	—	Acquired	550878	Direct
2015-10-06	Common Stock	J	80	$8.60	Acquired	550958	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-10-06	Series C-2 Convertible Preferred Stock	$	C	3655	Disposed		Common Stock (2672)	Direct

Footnotes

F1: The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.

F2: The Reporting Person received a total of 80 shares of the Issuer's common stock which represented a payment-in-kind dividend on 3,655 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.